Shanghai iCELL Biotechnology Co Ltd, located in the Changning area of the Hongqiao International Central Business District, was recently recognized as a national "little giant" firm.
The announcement was made by the Shanghai Municipal Commission of Economy and Information Technology.
The term "little giants" refers to those innovation-driven small and medium-sized enterprises, which own core technologies in a niche market and show great market potential.
In recent years, they've become the focus of national development and are seen as pioneers in leading the next round of national sci-tech and economic development.
Founded in 2010, iCELL Biotechnology is an innovative cellular medicine research and development company focusing on advancing novel drugs derived from stem cells and immune cells.
The company boasts multiple clinical-stage candidate drugs and leads national key R&D projects on stem cell technologies.
With a high-caliber research and management team, iCELL Biotechnology has established standardized platforms for cellular drug R&D and commercialization. They're equipped with good manufacturing practice or GMP-compliant cell preparation centers and tissue banks across China, including in Shanghai, Beijing, Guangzhou, Chongqing, Hangzhou and Xuzhou cities.
Collaborating closely with dozens of domestic and international research institutions and medical facilities, iCELL Biotechnology is actively engaged in scientific studies, clinical trials and translational applications in the field of cell therapy.
